Would Negative Interim PET Be Enough to Omit Radiation in Patients With Early Hodgkin Lymphoma? The Answer Is No

The patient in question, with both B symptoms and bulky disease, belongs to an intermediate group in which disease can be considered advanced and treated with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone if we follow the German Hodgkin's Study HD 11 criteria.1 Many others still treat this group as an early unfavorable disease using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). This is particularly important in explaining the treatment options presented here.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research